M2 macrophage immunotherapy abolishes glucose intolerance by increasing IL-10 expression and AKT activation

Immunotherapy. 2020 Jan;12(1):9-24. doi: 10.2217/imt-2019-0080. Epub 2020 Jan 9.

Abstract

Aim: Glucose intolerance associates with M1/M2 macrophage unbalance. We thus wanted to examine the effect of M2 macrophage administration on mouse model of glucose intolerance. Materials & methods: C57BL/6 mice fed a high-fat diet (HFD) for 12 weeks and then received thrice 20 mg/kg streptozotocin (HFD-GI). Bone marrow-derived stem cells were collected from donor mice and differentiated/activated into M2 macrophages for intraperitoneal administration into HFD-GI mice. Results: M2 macrophage treatment abolished glucose intolerance independently of obesity. M2 macrophage administration increased IL-10 in visceral adipose tissue and serum, but showed no effect on serum insulin. While nitric oxide synthase-2 and arginase-1 remained unaltered, M2 macrophage treatment restored AKT phosphorylation in visceral adipose tissue. Conclusion: M2 macrophage treatment abolishes glucose intolerance by increasing IL-10 and phosphorylated AKT.

Keywords: AKT; Arg-1; IL-10; NOS-2; Type 2 diabetes; glucose intolerance; high-fat diet; macrophage; streptozotocin; visceral adipose tissue.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2 / immunology
  • Diabetes Mellitus, Type 2 / therapy*
  • Diet, High-Fat
  • Disease Models, Animal
  • Glucose Intolerance
  • Humans
  • Immunotherapy / methods*
  • Insulin Resistance
  • Interleukin-10 / genetics
  • Interleukin-10 / metabolism*
  • Macrophages / immunology*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Proto-Oncogene Proteins c-akt / metabolism*
  • Signal Transduction
  • Streptozocin
  • Th2 Cells / immunology

Substances

  • Interleukin-10
  • Streptozocin
  • Proto-Oncogene Proteins c-akt